Adam Feuerstein, STAT News - Biogen & FDA

The Financial Exchange Show - A podcast by The Financial Exchange Network

Categories:

Business

Adam Feuerstein, senior reporter at STAT News, joined the show for an enticing interview regarding his Boston Globe story about the FDA's approval of Biogen's new, controversial Alzheimer's drug. Adam discusses how exactly Biogen was able to get approval of this drug (Aduhelm), and why it remains a point of contention.